Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Epidaza (chidamide)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Chipscreen, Eisai, GNT Biotech, HUYA Bioscience, Meiji Seika

Drug class:

HDAC inhibitor

Related drugs:

‹

›

BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	chidamide Sensitive: A1 - Approval chidamide Sensitive : A1	chidamide Sensitive: A1 - Approval chidamide Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	chidamide Sensitive: B - Late Trials chidamide Sensitive : B	chidamide Sensitive: B - Late Trials chidamide Sensitive : B
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	chidamide Sensitive: C2 – Inclusion Criteria chidamide Sensitive : C2	chidamide Sensitive: C2 – Inclusion Criteria chidamide Sensitive : C2
KMT2D mutation	Diffuse Large B Cell Lymphoma	KMT2D mutation	Diffuse Large B Cell Lymphoma	chidamide Resistant: C3 – Early Trials chidamide Resistant : C3	chidamide Resistant: C3 – Early Trials chidamide Resistant : C3
HDAC1 amplification	Soft Tissue Sarcoma	HDAC1 amplification	Soft Tissue Sarcoma	PD1 inhibitor + chidamide Sensitive: C3 – Early Trials PD1 inhibitor + chidamide Sensitive : C3	PD1 inhibitor + chidamide Sensitive: C3 – Early Trials PD1 inhibitor + chidamide Sensitive : C3
TNFRSF8 negative	Peripheral T-cell Lymphoma	TNFRSF8 negative	Peripheral T-cell Lymphoma	chidamide Sensitive: C3 – Early Trials chidamide Sensitive : C3	chidamide Sensitive: C3 – Early Trials chidamide Sensitive : C3
PD-L1 expression	Non-Hodgkin’s Lymphoma	PD-L1 expression	Non-Hodgkin’s Lymphoma	sintilimab + chidamide Sensitive: C3 – Early Trials sintilimab + chidamide Sensitive : C3	sintilimab + chidamide Sensitive: C3 – Early Trials sintilimab + chidamide Sensitive : C3
IDH2 mutation + TP53 mutation	Acute Myelogenous Leukemia	IDH2 mutation + TP53 mutation	Acute Myelogenous Leukemia	venetoclax + chidamide Sensitive: C3 – Early Trials venetoclax + chidamide Sensitive : C3	venetoclax + chidamide Sensitive: C3 – Early Trials venetoclax + chidamide Sensitive : C3
IDH1 mutation + TP53 mutation	Acute Myelogenous Leukemia	IDH1 mutation + TP53 mutation	Acute Myelogenous Leukemia	venetoclax + chidamide Sensitive: C3 – Early Trials venetoclax + chidamide Sensitive : C3	venetoclax + chidamide Sensitive: C3 – Early Trials venetoclax + chidamide Sensitive : C3
TP53 mutation	Diffuse Large B Cell Lymphoma	TP53 mutation	Diffuse Large B Cell Lymphoma	chidamide Sensitive: C4 – Case Studies chidamide Sensitive : C4	chidamide Sensitive: C4 – Case Studies chidamide Sensitive : C4
ARID1A mutation	Lymphoma	ARID1A mutation	Lymphoma	chidamide Sensitive: C4 – Case Studies chidamide Sensitive : C4	chidamide Sensitive: C4 – Case Studies chidamide Sensitive : C4
MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma	MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma	doxorubicin hydrochloride + chidamide Sensitive: D – Preclinical doxorubicin hydrochloride + chidamide Sensitive : D	doxorubicin hydrochloride + chidamide Sensitive: D – Preclinical doxorubicin hydrochloride + chidamide Sensitive : D